Clinical Trials
17 trialsNCT06406465 2026-06-05
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05627245 2026-05-13
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03772925 2026-03-03
Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 1 Terminated
NCT02381548 2026-01-30
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00993616 2019-07-23
Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
National Cancer Institute (NCI)
Phase 2 Completed
NCT01273155 2019-03-26
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00926640 2018-10-19
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00301756 2018-08-20
Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00365053 2018-06-07
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00357032 2018-04-17
PXD101 in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00334789 2018-04-03
Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT00321594 2017-11-06
Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00589290 2015-09-30
Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00351975 2014-12-23
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
National Cancer Institute (NCI)
Phase 1 Completed
NCT00303953 2014-05-12
PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00354185 2013-05-16
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00348985 2013-05-03
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Completed